Obesity drug industry could be worth $200 billion within the decade, says Barclays, as market valuations grow

Obesity drug industry could be worth $200 billion within the decade, says Barclays, as market valuations grow

The burgeoning weight-loss drug industry, which is whetting investors’ appetites with its pledge of combating global obesity rates, could be worth as much as $200 billion within the next decade, according to Barclays bank.
Read the article on CNBC >

Read More from the Global Wellness News ™